Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: A prospective cohort study

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 1, 2016, Pages 44-51

  Ligthart, Symen ^a   van Herpt, Thijs T W ^a   Leening, Maarten J G ^a,b   Kavousi, Maryam ^a   Hofman, Albert ^a,b   Stricker, Bruno H C ^a,c   van Hoek, Mandy ^a   Sijbrands, Eric J G ^a   Franco, Oscar H ^a   Dehghan, Abbas ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Netherlands Health Care Inspectorate   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; GLUCOSE;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG USE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE METABOLISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; WAIST CIRCUMFERENCE; AGED; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; PREDIABETIC STATE;

AGED; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLUCOSE; HUMANS; MALE; MIDDLE AGED; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84955352966     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00362-9     Document Type: Article

References (32)

1. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007, 78:305-312.
2. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M Prediabetes: a high-risk state for diabetes development. Lancet 2012, 379:2279-2290.
3. Yeboah J, Bertoni AG, Herrington DM, Post WS, Burke GL Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2011, 58:140-146.
4. IDF Diabetes Atlas 2013, International Diabetes Federation, International Diabetes Federation, Brussels, Belgium. 6th edn.
5. (7) Approaches to glycemic treatment. Diabetes Care 2015, 38(suppl):S41-S48. American Diabetes Association.
6. Wallia A, Molitch ME Insulin therapy for type 2 diabetes mellitus. JAMA 2014, 311:2315-2325.
7. Turner RC, Cull CA, Frighi V, Holman RR, Group UKPDS Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012. the UK Prospective Diabetes Study (UKPDS) Group.
8. Lloyd-Jones DM, Larson MG, Beiser A, Levy D Lifetime risk of developing coronary heart disease. Lancet 1999, 353:89-92.
9. Feuer EJ, Wun L-M, Boring CC, Flanders WD, Timmel MJ, Tong T The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993, 85:892-897.
10. Narayan KMV, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290:1884-1890.
11. Gregg EW, Zhuo X, Cheng YJ, Albright AL, Narayan KM, Thompson TJ Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study. Lancet Diabetes Endocrinol 2014, 2:867-874.
12. Magliano DJ, Shaw JE, Shortreed SM, et al. Lifetime risk and projected population prevalence of diabetes. Diabetologia 2008, 51:2179-2186.
13. Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol 2013, 28:889-926.
14. Leening MJG, Kavousi M, Heeringa J, et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 2012, 27:173-185.
15. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation 2006, 1-50. World Health Organization, World Health Organization, Geneva.
16. Waist circumference and waist-hip ratio World Health Organization Expert Consultation, (accessed Nov 3, 2015). http://www.who.int/nutrition/publications/obesity/WHO_report_waistcircumference:and_waisthip_ratio/en/.
17. Irwin JO The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice. J Hyg (Lond) 1949, 47:188-189.
18. Allignol A, Schumacher M, Beyersmann J Empirical transition matrix of multistate models: the etm package. J Stat Softw 2011, 38:1-15.
19. Therneau TM Modeling survival data: extending the Cox model 2000, Springer.
20. Levitan EB, Song Y, Ford ES, Liu S Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004, 164:2147-2155.
21. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. the Emerging Risk Factors Collaboration.
22. Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841. the Emerging Risk Factors Collaboration.
23. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. the Diabetes Prevention Program Research Group.
24. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350. the Finnish Diabetes Prevention Study Group.
25. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105. the DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators.
26. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686. the Diabetes Prevention Program Research Group.
27. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014 2014, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA.
28. Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF Effect of BMI on lifetime risk for diabetes in the US. Diabetes Care 2007, 30:1562-1566.
29. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29:1963-1972.
30. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203. the American Diabetes Association, the European Association for Study of Diabetesthe European Association for Study of Diabetes.
31. Grant RW, Wexler DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care 2007, 30:1448-1453.
32. Leening MJG, Heeringa J, Deckers JW, et al. Healthy volunteer effect and cardiovascular risk. Epidemiology 2014, 25:470-471.